
RedShift BioAnalytics: Global manufacturer of bioanalytical instruments for protein-based drug development.
RedShift BioAnalytics develops and manufactures bioanalytical instruments for the biopharmaceutical industry. The company focuses on providing critical measurements for protein-based drug development, offering tools that deliver rapid and actionable information about protein structure and concentration. Their products cater to various stages of the biopharmaceutical process, from research and development to manufacturing and characterization of next-generation biotherapeutics.
The company serves research and development, life science, and biopharmaceutical markets worldwide. RedShift BioAnalytics aims to accelerate scientific progress by providing innovative analytical solutions that help biopharmaceutical scientists move their work forward more efficiently. Their commitment to sharpening the edge of innovation in biopharmaceutical analysis positions them as a key player in advancing protein-based drug development.

IonDX
iondx.com

BioAnalytix
bioanalytixinc.com

BioAnalytics
Thermo Fisher th
thermofisher.com

Revolution Biosciences

Solus Biosystems

Bio-Rad
bio-rad.com

908 Devices
908devices.com

Accium BioSciences

Protein Dynamic Solutions
pdsbio.com

Andson Biotech
andsonbiotech.com

Bioinformatics
bioinfoinc.com

Fluidigm
standardbio.com

Attometrics

GMJ Technologies
gmjtechs.com
Companies similar to RedShift BioAnalytics include IonDX, BioAnalytix, BioAnalytics and Thermo Fisher th.
RedShift BioAnalytics was founded in 2005.
RedShift BioAnalytics' headquarters is located in Burlington, MA, US.
RedShift BioAnalytics' most recent funding round was for $20M (USD) in October 2021.
As of Oct 18, 2021, RedShift BioAnalytics has raised a total of $65.7M (USD).
RedShift BioAnalytics has 33 employees as of Feb 5, 2024.